Literature DB >> 8390680

Optimizing transmembrane domain helicity accelerates insulin receptor internalization and lateral mobility.

E Goncalves1, K Yamada, H S Thatte, J M Backer, D E Golan, C R Kahn, S E Shoelson.   

Abstract

Transmembrane (TM) domains of integral membrane proteins are generally thought to be helical. However, a Gly-Pro sequence within the TM domain of the insulin receptor is predicted to act as a helix breaker. CD analyses of model TM peptides in a lipid-like environment show that substitution of Gly and Pro by Ala enhances helicity. On this basis, Gly933 and Pro934 within the TM domain of the intact human insulin receptor were mutated to Ala (G-->A, P-->A, GP-->AA) to assess effects of altered helicity on receptor functions. Mutated and wild-type receptors, expressed stably in cultured CHO cells at equivalent levels, were properly assembled, biosynthetically processed, and exhibited similar affinities for insulin. Receptor autophosphorylation and substrate kinase activity in intact cells and soluble receptor preparations were indistinguishable. In contrast, insulin-stimulated receptor internalization was accelerated 2-fold for the GP-->AA mutant, compared to a wild-type control or the G-->A and P-->A mutants. Insulin degradation, which occurs during receptor endocytosis and recycling, was similarly elevated in cells transfected with GP-->AA mutant receptors. Fluorescence photobleaching recovery measurements showed that the lateral mobility of GP-->AA mutant receptors was also increased 2- to 3-fold. These results suggest that lateral mobility directly influences rates of insulin-mediated receptor endocytosis and that rates of endocytosis and lateral mobility are retarded by a kinked TM domain in the wild-type receptor. Invariance of Gly-Pro within insulin receptor TM domain sequences suggests a physiologic advantage for submaximal rates of receptor internalization.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8390680      PMCID: PMC46802          DOI: 10.1073/pnas.90.12.5762

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  Fluorescent labeling of hormone receptors in viable cells: preparation and properties of highly fluorescent derivatives of epidermal growth factor and insulin.

Authors:  Y Shechter; J Schlessinger; S Jacobs; K J Chang; P Cuatrecasas
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

Review 2.  Uptake of insulin and other ligands into receptor-rich endocytic components of target cells: the endosomal apparatus.

Authors:  J J Bergeron; J Cruz; M N Khan; B I Posner
Journal:  Annu Rev Physiol       Date:  1985       Impact factor: 19.318

3.  Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells.

Authors:  J Schlessinger; Y Shechter; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

4.  Hypothesis about the function of membrane-buried proline residues in transport proteins.

Authors:  C J Brandl; C M Deber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

Review 5.  Empirical predictions of protein conformation.

Authors:  P Y Chou; G D Fasman
Journal:  Annu Rev Biochem       Date:  1978       Impact factor: 23.643

6.  The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling.

Authors:  Y Ebina; L Ellis; K Jarnagin; M Edery; L Graf; E Clauser; J H Ou; F Masiarz; Y W Kan; I D Goldfine
Journal:  Cell       Date:  1985-04       Impact factor: 41.582

7.  Mobility measurement by analysis of fluorescence photobleaching recovery kinetics.

Authors:  D Axelrod; D E Koppel; J Schlessinger; E Elson; W W Webb
Journal:  Biophys J       Date:  1976-09       Impact factor: 4.033

8.  Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes.

Authors:  A Ullrich; J R Bell; E Y Chen; R Herrera; L M Petruzzelli; T J Dull; A Gray; L Coussens; Y C Liao; M Tsubokawa
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

9.  Proline residues in transmembrane helices of channel and transport proteins: a molecular modelling study.

Authors:  M S Sansom
Journal:  Protein Eng       Date:  1992-01

10.  Schistosomula of Schistosoma mansoni use lysophosphatidylcholine to lyse adherent human red blood cells and immobilize red cell membrane components.

Authors:  D E Golan; C S Brown; C M Cianci; S T Furlong; J P Caulfield
Journal:  J Cell Biol       Date:  1986-09       Impact factor: 10.539

View more
  6 in total

1.  A mechanistic role for polypeptide hormone receptor lateral mobility in signal transduction.

Authors:  D A Jans; I Pavo
Journal:  Amino Acids       Date:  1995-06       Impact factor: 3.520

2.  Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking.

Authors:  S Giorgetti-Peraldi; E Ottinger; G Wolf; B Ye; T R Burke; S E Shoelson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

3.  Two chimeric receptors of epidermal growth factor receptor and c-Ros that differ in their transmembrane domains have opposite effects on cell growth.

Authors:  Q Xiong; J L Chan; C S Zong; L H Wang
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Hormone-triggered conformational changes within the insulin-receptor ectodomain: requirement for transmembrane anchors.

Authors:  R R Flörke; K Schnaith; W Passlack; M Wichert; L Kuehn; M Fabry; M Federwisch; H Reinauer
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

5.  Barriers for lateral diffusion of transferrin receptor in the plasma membrane as characterized by receptor dragging by laser tweezers: fence versus tether.

Authors:  Y Sako; A Kusumi
Journal:  J Cell Biol       Date:  1995-06       Impact factor: 10.539

6.  All-Atom Structural Models of the Transmembrane Domains of Insulin and Type 1 Insulin-Like Growth Factor Receptors.

Authors:  Hossein Mohammadiarani; Harish Vashisth
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-20       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.